---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-018748"
form_type: "8-K"
ticker: "HCA"
cik: "0000860730"
company_name: "HCA Healthcare, Inc."
filed_at: "2024-01-30T23:59:59+00:00"
generated_at: "2026-06-06T15:32:42.504520+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# HCA Healthcare Q4 revenue up 11.6% to $17.3B; FY2024 EPS guidance $19.70-$21.20; CFO succession announced

## Summary
- Q4 2023 revenue $17.303B (+11.6% YoY); net income $1.607B ($5.93 diluted EPS) vs $2.081B ($7.28) in Q4 2022, which included $1.326B gain.
- Adjusted EBITDA $3.618B (up from $3.179B); same facility admissions +3.1%, equivalent admissions +3.9%.
- FY2024 guidance: revenue $67.75-$70.25B, Adjusted EBITDA $12.85-$13.55B, diluted EPS $19.70-$21.20; capex $5.1-$5.3B.
- Board authorized additional $6B share repurchase program; quarterly dividend declared at $0.66 per share (unchanged).
- CFO Bill Rutherford retiring May 1, 2024; succeeded by Mike Marks, current SVP Finance.

## SEC filing metadata
- accession: 0001193125-24-018748
- form_type: 8-K
- ticker: HCA
- cik: 0000860730
- company_name: HCA Healthcare, Inc.
- filed_at: 2024-01-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/860730/000119312524018748/0001193125-24-018748-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/860730/000119312524018748/d734797d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-018748
- JSON: https://secwatch.observer/filing/0001193125-24-018748.json
- Plain text: https://secwatch.observer/filing/0001193125-24-018748.txt

## Key facts
- Earnings Releases
  HCA Healthcare, Inc. reported 2024 results: revenue $67.75 to $70.25 billion, net income $5.20 to $5.60 billion, EPS $19.70 to $21.20 per diluted share. Guidance initiated.
  - Period: 2024
  - Revenue: $67.75 to $70.25 billion
  - Net income: $5.20 to $5.60 billion
  - EPS: $19.70 to $21.20 per diluted share
  - Guidance: initiated
  - Result: guidance update
  source text: Today, the Company issued the following estimated guidance for 2024: 2024 Guidance Range Revenues $67.75 to $70.25 billion Net Income Attributable to HCA Healthcare, Inc. $5.20 to $5.60 billion Adjusted EBITDA $12.85 to $13.55 billion EPS (diluted) $19.70 to $21.20 per diluted share
  evidence_url: https://www.sec.gov/Archives/edgar/data/860730/000119312524018748/0001193125-24-018748-index.htm
- Earnings Releases
  HCA Healthcare, Inc. reported the year ended December 31, 2023 results: revenue $64.968 billion, net income $5.242 billion, EPS $18.97 per diluted share. Guidance initiated.
  - Period: the year ended December 31, 2023
  - Revenue: $64.968 billion
  - Net income: $5.242 billion
  - EPS: $18.97 per diluted share
  - Guidance: initiated
  - Result: reported results
  source text: Revenues for the year ended December 31, 2023 totaled $64.968 billion, compared to $60.233 billion for the year ended December 31, 2022. Net income attributable to HCA Healthcare, Inc. was $5.242 billion, or $18.97 per diluted share, for the year ended December 31, 2023 compared to $5.643 billion, or $19.15 per diluted share, for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/860730/000119312524018748/0001193125-24-018748-index.htm
- Earnings Releases
  HCA Healthcare, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $17.303 billion, net income $1.607 billion, EPS $5.93 per diluted share. Guidance initiated.
  - Period: the fourth quarter ended December 31, 2023
  - Revenue: $17.303 billion
  - Net income: $1.607 billion
  - EPS: $5.93 per diluted share
  - Guidance: initiated
  - Result: reported results
  source text: Revenues in the fourth quarter of 2023 totaled $17.303 billion, compared to $15.497 billion in the fourth quarter of 2022. Net income attributable to HCA Healthcare, Inc. totaled $1.607 billion, or $5.93 per diluted share, compared to $2.081 billion, or $7.28 per diluted share, in the fourth quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/860730/000119312524018748/0001193125-24-018748-index.htm
- Executive change
  Michael A. Marks was appointed as Executive Vice President and Chief Financial Officer at HCA Healthcare, Inc..
  - Action: appointed
  - Role: Executive Vice President and Chief Financial Officer
  source text: On January 30, 2024, the Company announced that Michael A. Marks, age 54, will succeed Mr. Rutherford as Executive Vice President and Chief Financial Officer, effective May 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/860730/000119312524018748/0001193125-24-018748-index.htm
- Executive change
  William B. Rutherford retired as Executive Vice President and Chief Financial Officer at HCA Healthcare, Inc..
  - Action: retired
  - Role: Executive Vice President and Chief Financial Officer
  source text: On January 24, 2024, William B. Rutherford notified the Company of his intent to retire from his position as Executive Vice President and Chief Financial Officer, effective May 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/860730/000119312524018748/0001193125-24-018748-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.